Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADRB2 | P07550 | 4/20 | 0.50 |
| ▸ | HTR1D | P28221 | 1/20 | 0.50 |
| ▸ | HTR2A | P28223 | 1/20 | 0.46 |
| ▸ | NQO2 | P16083 | 1/20 | 0.46 |
| ▸ | MTNR1A | P48039 | 1/20 | 0.46 |
| ▸ | MTNR1B | P49286 | 1/20 | 0.46 |
| ▸ | SPR | P35270 | 1/20 | 0.45 |
| ▸ | HTR6 | P50406 | 3/20 | 0.42 |
| ▸ | GPR84 | Q9NQS5 | 1/20 | 0.40 |
| ▸ | SNCA | P37840 | 1/20 | 0.38 |
| ▸ | CDK2 | P24941 | 2/20 | 0.37 |
| ▸ | PRKCI | P41743 | 1/20 | 0.37 |
| ▸ | MEN1 | O00255 | 2/20 | 0.36 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3320875 | 0.84 | HTR1D (0.68) | ADRB2HTR1DHTR2ANQO2MTNR1A | |
| SCHEMBL28847185 | 0.82 | SPR (0.64) | ADRB2HTR1DHTR2ANQO2MTNR1A | |
| SCHEMBL14302712 | 0.82 | SNCA (0.53) | ADRB2HTR1DNQO2MTNR1AMTNR1B | |
| SCHEMBL3698621 | 0.82 | MPO (0.51) | ADRB2HTR1DHTR2ANQO2MTNR1A | |
| SCHEMBL9400590 | 0.79 | ADRB2 (0.49) | ADRB2HTR1DHTR2ANQO2MTNR1A | |
| SCHEMBL3348930 | 0.79 | HTR6 (0.66) | ADRB2HTR1DHTR2AHTR6 | |
| SCHEMBL3257855 | 0.78 | GPR84 (0.68) | HTR2AHTR6GPR84MEN1KMT2A | |
| SCHEMBL9597232 | 0.77 | NQO2 (0.43) | ADRB2HTR1DHTR2ANQO2MTNR1A | |
| SCHEMBL3355548 | 0.77 | HTR1D (0.48) | ADRB2HTR1DHTR2AHTR6 | |
| SCHEMBL18509874 | 0.77 | HPGD (0.51) | ADRB2HTR1DHTR2ANQO2MTNR1A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100120886-A1 | ARYL-SUBSTITUTED SULFONAMIDES FOR THE TREATMENT OF COGNITIVE OR FOOD INGESTION RELATED DISORDERS | LABORATORIOS DEL DR. ESTEVE, S.A. (ES) | 2010-05-13 | — | — | US | claimed |
| EP-1953141-A1 | Aryl-substituted sulfonamides for the treatment of cognitive or food ingestion related disorders | Laboratorios del Dr. Esteve S.A. (ES) | 2008-08-06 | — | — | EP | claimed |
| US-20100120886-A1 | ARYL-SUBSTITUTED SULFONAMIDES FOR THE TREATMENT OF COGNITIVE OR FOOD INGESTION RELATED DISORDERS | LABORATORIOS DEL DR. ESTEVE, S.A. (ES) | 2010-05-13 | — | — | US | disclosed |
| EP-1953141-A1 | Aryl-substituted sulfonamides for the treatment of cognitive or food ingestion related disorders | Laboratorios del Dr. Esteve S.A. (ES) | 2008-08-06 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100120886-A1 | ARYL-SUBSTITUTED SULFONAMIDES FOR THE TREATMENT OF COGNITIVE OR FOOD INGESTION RELATED DISORDERS | HTR6, HTR2A, HTR2C | ADRB2 1596/4885HTR1D 19/4885HTR2A 2/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.